Literature DB >> 9221814

Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors.

R Rosell1, A Pifarré, M Monzó, J Astudillo, M P López-Cabrerizo, R Calvo, I Moreno, M Sanchez-Céspedes, A Font, J J Navas-Palacios.   

Abstract

To better understand whether replication-error-type instability (RER+) is a frequent genetic alteration event in surgical-pathologic stage-I non-small-cell lung cancer (NSCLC) and identify whether it constitutes an independent prognostic parameter, we examined 35 surgical-pathologic stage-I-NSCLC patients with complete follow-up in all cases for at least 49 months. The tumor samples and the paired histopathologically normal lung samples for each patient were analyzed for 8 microsatellite markers located at chromosomes 3p and 2p to investigate microsatellite alterations such as RER+ and loss of heterozygosity (LOH). Single-strand-conformation-polymorphism analysis for detection of p53 and k-ras gene mutations was also carried out. Genetic data were correlated with clinical outcome and histopathologically established prognostic factors. RER+ at one or both chromosomes was identified in 24 of the 35 patients; 9 patients showed LOH. A statistically significant correlation was found between RER+ and poor prognosis (p = 0.001). Furthermore, RER+ proved to be an independent factor that predicted decreased survival, ranking first, followed by visceral pleural invasion. A trend towards worse survival was strongest in the group of patients with tumor size greater than 3 cm (T2). Patients with other genetic abnormalities, such as K-ras mutations, p53 mutations or LOH, had prognoses similar to those of patients without such aberrations. The data suggest that RER+ is common in NSCLC, that it may provide important prognostic information in stage-I NSCLC and serve as a useful marker for relapse-risk assessment in operable NSCLC patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9221814     DOI: 10.1002/(sici)1097-0215(19970620)74:3<330::aid-ijc17>3.0.co;2-f

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Histotype-based prognostic classification of gastric cancer.

Authors:  Anna Maria Chiaravalli; Catherine Klersy; Alessandro Vanoli; Andrea Ferretti; Carlo Capella; Enrico Solcia
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

3.  A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.

Authors:  Katherine S Garman; Chaitanya R Acharya; Elena Edelman; Marian Grade; Jochen Gaedcke; Shivani Sud; William Barry; Anna Mae Diehl; Dawn Provenzale; Geoffrey S Ginsburg; B Michael Ghadimi; Thomas Ried; Joseph R Nevins; Sayan Mukherjee; David Hsu; Anil Potti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-02       Impact factor: 11.205

4.  Analysis of microsatellite mutations in buccal cells from a case-control study for lung cancer.

Authors:  Jessica L Baumann; Ming Li; Aslak Poulsen; Nicholson S Chadwick; Qiuyin Cai; Christine H Chung; Yu Shyr; Jørgen H Olsen; Wei Zheng; Robbert J C Slebos
Journal:  Cancer Epidemiol       Date:  2011-11-06       Impact factor: 2.984

5.  Analysis of the expression protein profiles of lung squamous carcinoma cell using shot-gun proteomics strategy.

Authors:  Yandong Nan; Shuanying Yang; Yingxuan Tian; Wei Zhang; Bin Zhou; Lina Bu; Shufen Huo
Journal:  Med Oncol       Date:  2008-11-06       Impact factor: 3.064

6.  ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy.

Authors:  Jong-Mu Sun; Ji-Youn Sung; Se Hoon Park; Ghee Young Kwon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Jisuk Jo; Han Yong Choi; Ho Yeong Lim
Journal:  BMC Cancer       Date:  2012-05-22       Impact factor: 4.430

Review 7.  The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.

Authors:  C Mascaux; N Iannino; B Martin; M Paesmans; T Berghmans; M Dusart; A Haller; P Lothaire; A-P Meert; S Noel; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

8.  Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy.

Authors:  Ruoxin Zhang; Ming Jia; Huijing Xue; Yuan Xu; Mengyun Wang; Meiling Zhu; Menghong Sun; Jianhua Chang; Qingyi Wei
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

9.  Effect of etoposide-induced alteration of the Mdm2-Rb signaling pathway on cellular senescence in A549 lung adenocarcinoma cells.

Authors:  Wenjing Dai; Yi Jiang; Kairong Chen; Jing Qiu; Jian Sun; Wei Zhang; Xiafei Zhou; Na Huang; Yunhui Li; Wancheng Li
Journal:  Oncol Lett       Date:  2017-07-27       Impact factor: 2.967

Review 10.  Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers.

Authors:  Milena Matuszczak; Maciej Salagierski
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.